Clinical Trials Logo
  1. Home
  2. Neuroendocrine Carcinoma
  3. NCT03278405

Avelumab in G3 NEC — NET-001  

Neuroendocrine Carcinoma Clinical Trial

Official title:
A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas

Clinical Trial Summary

This is a single-center, single-arm, open-label, pilot trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 3, poorly-differentiated neuroendocrine.carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03278405
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 15, 2017
Completion date March 12, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01642251 - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04069299 - Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting NCT04325425 - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary Phase 2
Completed NCT03834701 - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms N/A
Recruiting NCT03279614 - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05978284 - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Phase 1/Phase 2
Recruiting NCT05076786 - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma Phase 2
Completed NCT00388063 - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Withdrawn NCT03901378 - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Phase 2
Recruiting NCT02970786 - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans Phase 1
Completed NCT00663429 - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Active, not recruiting NCT03837977 - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Active, not recruiting NCT02687958 - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Phase 2
Completed NCT01121939 - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Phase 2
Recruiting NCT03168607 - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Enrolling by invitation NCT05396118 - Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients Phase 2
Completed NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Phase 2